Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a pilot study looking at the safety and efficacy of giving combination chelation with deferasirox and deferoxamine. The hypothesis is that combination chelation is safe in decreasing overall iron in patients with thalassemia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Hospital & Research Center Oakland; Elliott Vichinsky
• Treatments: Deferasirox; Deferoxamine; Iron

Criteria

Inclusion Criteria:

• Transfusion Dependent Thalassemia

• If iron between 5-15 mg/g dry liver by SQUID, subject must have a documented endocrinopathy or cardiac finding

• Older than 8 years

Exclusion Criteria:

• Participating on another interventional clinical trial